University of Tokyo, Astellas Enters the Second Phase of Strategic Partnership

0 66

The Astellas Alliance Acceleration Program (AAAP), a collaboration between the University of Tokyo and Astellas Pharma Inc. for co-creating revolutionary new medicines and medical solutions, started today.

AAAP established a foundation for its collaborative connection at the university’s Institute for Life Science Research and Education, as well as the University of Tokyo Center of Innovation, in its first phase, which ran from September 2020 to March 2022. During this time, medical and pharmaceutical researchers from the two universities, as well as drug development experts from Astellas, created a climate conducive to open-minded talks, resulting in the identification and successful launch of several new research initiatives.

“Encouraged by our close collaboration during the first phase, we are delighted to start the second phase encompassing the breadth of research at the University of Tokyo. We hope that comprehensive knowledge of the life sciences from the university will further lead to innovative drug discovery projects,”

said Hidenori Ichijo, DDS, Ph.D., a professor at the university’s Graduate School of Pharmaceutical Sciences and a member of the AAAP Steering Committee.

The University of Tokyo will increase its collaboration involvement in the second phase to encompass all of its institutions. In addition, to facilitate the collaboration, a newly recruited AAAP-dedicated project manager will be stationed at the university. By integrating the University of Tokyo’s cutting-edge scientific research with Astellas’ drug discovery know-how, the strategic partners will be able to develop new research projects.

“In this phase, we will further pursue interdisciplinary collaboration, such as in the fields of engineering and the life sciences, by tapping into the broad range of research at the University of Tokyo,”

Professor Yuichi Tei / Ungil Chung, M.D., Ph.D., of the university’s Graduate School of Engineering and Graduate School of Medicine, also a member of the AAAP Steering Committee, said.

By fostering the production of value via discussion and empathy with society, the University of Tokyo hopes to find solutions to society’s issues and contribute to the development of business.

“I am pleased with this AAAP second phase agreement, By leveraging the power of the more extensive and closer collaboration, we expect to accelerate the co-creation of innovations that contribute to our activities from early drug discovery research to clinical development,”

said Yoshitsugu Shitaka, Ph.D., Chief Scientific Officer at Astellas.

Under its corporate strategy of “contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products,” Astellas is dedicated to developing unique medical solutions that transform innovative science into VALUE for patients. The University of Tokyo and Astellas will collaborate closely to promote innovation by sharing a shared vision and problems.

Contact us with your feedback and suggestions.

Leave A Reply

Your email address will not be published.